KRT-232 and navitoclax enhance trametinib’s anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations

Activating mutations of the KRAS gene are one of the major genomic alterations associated with tumorigenesis of non-small cell lung cancer (NSCLC). Thus far, treatment of KRAS-mutant NSCLC remains an unmet medical need. We determined the in vivo treatment responses of 13 KRAS mutant and 14 KRAS wild...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Main Authors: Zhang, Xiaoshan, Zhang, Ran, Chen, Huiqin, Wang, Li, Ren, Chenghui, Pataer, Apar, Wu, Shuhong, Meng, Qing H, Ha, Min Jin, Morris, Jeffrey, Xi, Yuanxin, Wang, Jing, Zhang, Jianhua, Gibbons, Don L, Heymach, John V, Meric-Bernstam, Funda, Minna, John, Swisher, Stephen G, Roth, Jack A, Fang, Bingliang
Formato: Artigo
Idioma:Inglês
Publicado: e-Century Publishing Corporation 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783771/
https://ncbi.nlm.nih.gov/pubmed/33415011
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares